MonoFer® (Iron Isomaltoside)

MonoFer® (Iron Isomaltoside)

Monofer® is used for treating iron deficiency with and without anaemia when oral iron preparations are ineffective or cannot be used or when there is a need to deliver iron rapidly.


Approved in more than 36 countries globally with more than 10 million doses administered*
*based on Pharmacosmos A/S data on file, Dec 2017 (based on the WHO defined daily dose of 100mg and including doses  of iron isomoltoside under all applicable trade names)



Good safety profile

  • No dose dependency of ADRs
  • Low level of labile iron



  • Meeting patient iron needs in just one visit
  • Single dose up to 20mg/kg - no other dose limits
  • No test dose required



  • Fewer patient visits
  • Reduces waiting lists
  • Frees up treatment capacity
  • Designed for treatment of ID across multiple therapeutic areas

    • Nephrology
    • Gastroenterology
    • Obstetrics / Gynaecology
    • Surgery
    • Haematology
    • Oncology
    • Cardiology

Quicklinks >>

Compai Pharma strives to improve the lives of patients by providing access to essential products and medical devices. 

Compai Pharma,  Singapore

T: +65 9724 4136
18 Duxton Hill, Singapore 089601

Compai Pharma, Malaysia

T:  +603 7625 1636

Compai Healthcare Sdn. Bhd, Unit 501, Block B, Pusat Dagangan Phileo Damansara II, No.15, Jalan 16/11, Off Jalan Damansara, 46350 Petaling Jaya, Selangor Darul Ehsan, Malaysia

Company No. 1255159–H

Compai Safety No : + 601 1118 63244  

Privacy Policy   .   Terms of Use  .   Registration  & License

© 2018 Compai Pharma Pte. Ltd. All Rights Reserved.

pharmaceuticals; medical devices, pharmaceutical distribution, in-licensing, registration, disease awareness, pharma sales and marketing, asia, Singapore, Malaysia,